• Explore /
  • Poster
  • / Preliminary safety and efficacy of perioperative COI-B (capecitabine, oxaliplatin, irinotecan, and bevacizumab) in patients with borderline resectable or high–recurrence risk colorectal cancer liver metastases (CLM).

Preliminary safety and efficacy of perioperative COI-B (capecitabine, oxaliplatin, irinotecan, and bevacizumab) in patients with borderline resectable or high–recurrence risk colorectal cancer liver metastases (CLM).

Abstract Poster

Authors

null

Marta Caporale

IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Marta Caporale , Christian Cotsoglou , Rosa Berenato , Mauro Scotti , Maria Di Bartolomeo , Jorgelina Clara Coppa , Massimo Milione , Alessia Mennitto , Maria Flores Reyes , Ilaria Bossi , Paola Valentina Consonni , Federica Brunero , Filippo de Braud , Filippo Pietrantonio , Vincenzo Mazzaferro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02086656

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr 719)

DOI

10.1200/jco.2016.34.4_suppl.719

Abstract #

719

Poster Bd #

L16

Abstract Disclosures

Similar Posters

First Author: Hideaki Bando

First Author: Johanna C. Bendell

First Author: Hironaga Satake

First Author: Hideaki Bando